Navigation Links
Castrate resistant prostate cancer: New therapeutic approaches
Date:3/20/2009

Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.

"If we look at the way kidney cancer treatment has changed over recent years we see a glimpse of the future", says Dr Gleave, "Targeted therapies may become available".

Recent studies indicate that tumour cells can develop an ability to synthesise enzymes to produce their own androgens for androgen receptor (AR) activation after castration.

CRPC tumours are not uniformly hormone resistant and may remain sensitive to therapies directed against the ARs. Dr Gleave: "Several new classes of AR-targeting agents are now in clinical development, including the 2nd generation anti-androgen MDV3100, abiraterone, and Hsp27 (OGX-427)".

The growth of new blood vessels, angiogenesis, plays an essential role in prostate cancer development and metastasis. "Among the various angiogenic targets implicated in tumour angiogenesis, vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, and its receptor have evoked a lot of interest," according to Dr Gleave. Bevacizumab targets VEGF and is a promising angiogenesis inhibitor in this indication. Other agents in late stage trials include sunitinib.

Clusterin is a stress-induced, multi-functional, molecular chaperone. A novel, phase I pre-prostatectomy trial defined the optimal biologically dose and toxicity parameters of OGX-011 with maximal knockdown of clusterin in prostate and lymph node tissues at the 640 mg dose level. A phase II study includes 81 men with CRPC to receive either docetaxel and OGX-11 (n=40) or docetaxel alone (n=41).

"All in all, we need to move forward with the momentum and continue to let biology guide treatment developments", said Gleave, who also expressed his gratitude for being invited to speak at the 24th Annual EAU Congress.


'/>"/>

Contact: lindy brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Recession-resistant Marketing Requires Innovative Steps
2. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
3. Mercy Hospital at Folsom Acquires Advanced Germicidal Technology to Battle MRSA, C. diff, Acinetobacter and Other Drug-Resistant Pathogens
4. Concerted Effort Needed to Fight Drug-Resistant Flu Strain
5. Antibiotic Combo Fights Resistant TB
6. A Recession-Resistant Business? Introducing FertilityAuthority.com
7. Antibiotic-Resistant Meningitis Reported in U.S.
8. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
9. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
10. Study shows rise in antibiotic resistant pediatric head and neck infections
11. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 2017 , ... A minimally invasive porcelain veneer is increasing ... Association of Dental Laboratories (NADL) is informing dentists about the benefits of minimally ... dental laboratories and technicians that create these veneers. , According to National ...
(Date:3/28/2017)... Kennett Square, PA (PRWEB) , ... March 28, 2017 , ... ... reputation online and across a variety of business channels. , While many results ... aspects of any public relations program. , When it comes to measurement, firms ...
(Date:3/28/2017)... Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... treatment, is proud to announce a new blog post about women’s hair loss. Although ... suffer from hair loss as they age. Menopause or genetics can be two reasons ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ... 8IS) Invictus MD is pleased to announce it has ... trading on the TSX Venture Exchange.  ... a year of significant achievements for Invictus-MD. Some of ... crops at AB Laboratories Inc. ("AB Labs"), a Licensed ...
Breaking Medicine Technology: